Back مختبرات دكتور ريدي Arabic مختبرات دكتور ريدى ARZ دوکتور ردی لابراتورو AZB Dr. Reddy’s Laboratories German آزمایشگاه دکتر ردی Persian Dr. Reddy's Laboratories Finnish Dr. Reddy's French डॉ. रेड्डीज लेबोरेटरीज Hindi Dr. Reddy's Laboratories ID ಡಾ. ರೆಡ್ಡೀ'ಸ್ ಲ್ಯಾಬೋರೇಟರೀಸ್ Kannada
 | |
| Company type | Public |
|---|---|
| NSE: DRREDDY BSE: 500124 NYSE: RDY NSE NIFTY 50 constituent | |
| ISIN | INE089A01023 |
| Industry | Pharmaceuticals |
| Founded | 1984 |
| Founder | Anji Reddy |
| Headquarters | Hyderabad, Telangana, India |
Area served | Worldwide |
Key people | G. V. Prasad (Co-Chairman & MD) Kallam Satish Reddy (Chairman) Erez Israeli (CEO) |
| Products | |
| Revenue |  ₹28,905 crore (US$3.5 billion) (FY24)[1] |
| ₹7,201 crore (US$860 million) (FY24)[1] | |
| ₹5,577 crore (US$670 million) (FY24)[1] | |
| Total assets | ₹38,863 crore (US$4.7 billion) (FY24)[1] |
| Total equity | ₹28,254 crore (US$3.4 billion) (FY24)[1] |
Number of employees | 24,832 (March 2023) |
| Website | www |
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.[2] Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.[3]
- ^ a b c d e "IND AS Consolidated Q4 FY 2023-24" (PDF). Dr. Reddy’s Laboratories. Retrieved 19 May 2024.
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 25 May 2014. Retrieved 24 May 2014.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Dr Reddy's Laboratories 2007-2012 – MarketReports.com 2007 life sciences research report, Technology Networks, Sudbury, Essex, UK Archived 19 January 2010 at the Wayback Machine.Accessed: 22 August 2007.